{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T02:28:03Z","timestamp":1779416883575,"version":"3.53.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["ERC-AdG-2020-101021417"],"award-info":[{"award-number":["ERC-AdG-2020-101021417"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100027385","name":"Southeastern Connecticut Cultural Coalition","doi-asserted-by":"publisher","award":["P30CA142543"],"award-info":[{"award-number":["P30CA142543"]}],"id":[{"id":"10.13039\/100027385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA283935"],"award-info":[{"award-number":["U01CA283935"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA282178"],"award-info":[{"award-number":["R01CA282178"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA233794"],"award-info":[{"award-number":["R01CA233794"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA288375"],"award-info":[{"award-number":["U01CA288375"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA255621"],"award-info":[{"award-number":["R01CA255621"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K08049"],"award-info":[{"award-number":["JP22K08049"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K27577"],"award-info":[{"award-number":["JP23K27577"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR180016"],"award-info":[{"award-number":["RR180016"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200554"],"award-info":[{"award-number":["RP200554"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018790","name":"National Institutes for Quantum Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","award":["ESR-19-20168"],"award-info":[{"award-number":["ESR-19-20168"]}],"id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jhepr.2026.101765","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:26:38Z","timestamp":1770337598000},"page":"101765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6540-9064","authenticated-orcid":false,"given":"Sadahisa","family":"Ogasawara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Koroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Makishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Fujiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Yumita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kanzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4080-2967","authenticated-orcid":false,"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Kanogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-8932","authenticated-orcid":false,"given":"Yoshihito","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8659-2873","authenticated-orcid":false,"given":"Yosuke","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumith","family":"Paritala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-7157","authenticated-orcid":false,"given":"Jeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9430-1426","authenticated-orcid":false,"given":"Yujin","family":"Hoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101765_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101765_bib2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101765_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41575-019-0229-4","article-title":"Tumour evolution in hepatocellular carcinoma","volume":"17","author":"Craig","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101765_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101765_bib5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101765_bib6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","article-title":"Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion","volume":"65","author":"Kokudo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101765_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2026.101765_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000513706","article-title":"Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar of the portal vein","volume":"10","author":"Kosaka","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101765_bib9","first-page":"8","article-title":"Assessment of macrovascular invasion in advanced hepatocellular carcinoma: clinical implications and treatment outcomes with systemic therapy","volume":"14","author":"Inoue","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101765_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101765_bib11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101765_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2026.101765_bib13","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101765_bib14","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101765_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101765_bib16","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1111\/liv.13969","article-title":"Short-course carbon-ion radiotherapy for hepatocellular carcinoma: a multi-institutional retrospective study","volume":"38","author":"Shibuya","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101765_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000520277","article-title":"Efficacy and safety of 4 fractions of carbon-ion radiation therapy for hepatocellular carcinoma: a prospective study","volume":"11","author":"Shibuya","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101765_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/cancers10030066","article-title":"Evolution of carbon ion radiotherapy at the national Institute of radiological sciences in Japan","volume":"10","author":"Mohamad","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2026.101765_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10147-017-1190-2","article-title":"A systematic review of publications on charged particle therapy for hepatocellular carcinoma","volume":"23","author":"Igaki","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101765_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/jrr\/rrw028","article-title":"Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis\/inferior vena cava tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy","volume":"57","author":"Matsuo","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.jhepr.2026.101765_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2017.11.013","article-title":"Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis and systematic review","volume":"129","author":"Rim","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jhepr.2026.101765_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12885-024-12154-4","article-title":"Carbon-ion radiotherapy for hepatocellular carcinoma with major vascular invasion: a retrospective cohort study","volume":"24","author":"Kaneko","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2026.101765_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705361","article-title":"Immunogenic cell death induction by ionizing radiation","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101765_bib24","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/cancers13040678","article-title":"Enhance the immune checkpoint inhibitors efficacy with radiotherapy induced immunogenic cell death: a comprehensive review and latest developments","volume":"13","author":"Procureur","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2026.101765_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059779","article-title":"Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial","volume":"12","author":"Ogasawara","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhepr.2026.101765_bib26","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1088\/0031-9155\/55\/22\/008","article-title":"Treatment planning for a scanned carbon beam with a modified microdosimetric kinetic model","volume":"55","author":"Inaniwa","year":"2010","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.jhepr.2026.101765_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1088\/0031-9155\/53\/1\/003","article-title":"Biophysical calculation of cell survival probabilities using amorphous track structure models for heavy-ion irradiation","volume":"53","author":"Kase","year":"2008","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.jhepr.2026.101765_bib28","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1002\/cncr.30816","article-title":"Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: combined analyses of 2 prospective trials","volume":"123","author":"Kasuya","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2026.101765_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13014-019-1347-4","article-title":"A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study","volume":"14","author":"Shiba","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jhepr.2026.101765_bib30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13014-020-01634-z","article-title":"Clinical impact of hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma","volume":"15","author":"Shiba","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jhepr.2026.101765_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jjco\/hyw144","article-title":"Respiration-gated fast-rescanning carbon-ion radiotherapy","volume":"47","author":"Ebner","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101765_bib32","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/cancers17152542","article-title":"Adverse events after carbon-ion radiotherapy (CIRT) for hepatocellular carcinoma and risk factors for biliary stricture after CIRT: a retrospective study","volume":"17","author":"Maki","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2026.101765_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2020.07.035","article-title":"Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis","volume":"151","author":"Sha","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jhepr.2026.101765_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.14338\/IJPT-18-00024.1","article-title":"Combining heavy-ion therapy with immunotherapy: an update on recent developments","volume":"5","author":"Helm","year":"2018","journal-title":"Int J Part Ther"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101765_bib35","doi-asserted-by":"crossref","first-page":"633","DOI":"10.18632\/oncotarget.26551","article-title":"Carbon ion irradiation enhances the antitumor efficacy of dual immune checkpoint blockade therapy both for local and distant sites in murine osteosarcoma","volume":"18","author":"Takahashi","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2026.101765_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310565","article-title":"A phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): the early safety and efficacy results","volume":"24","author":"Okonogi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2026.101765_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2021.08.021","article-title":"Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma","volume":"164","author":"Cavalieri","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jhepr.2026.101765_bib38","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/hepr.13827","article-title":"Carbon-ion radiotherapy versus radiofrequency ablation as initial treatment for early-stage hepatocellular carcinoma","volume":"52","author":"Fujita","year":"2022","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2026.101765_bib39","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/03008916241291341","article-title":"Preoperative chemo-CIRT in Re\/BRe pancreatic cancer: insights from a multicenter prospective phase II clinical study (NCT03822936)","volume":"110","author":"Barcellini","year":"2024","journal-title":"Tumori"},{"key":"10.1016\/j.jhepr.2026.101765_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cncr.27723","article-title":"Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer","volume":"119","author":"Shinoto","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2026.101765_bib41","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101765_bib42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.jhepr.2026.101765_bib43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhepr.2026.101765_bib44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/15384047.2016.1264543","article-title":"Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone","volume":"18","author":"Koller","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jhepr.2026.101765_bib45","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101765_bib46","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101765_bib47","article-title":"Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: a phase II study","volume":"6","author":"Kim","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101765_bib48","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jhepr.2026.101765_bib49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101765_bib50","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s00066-009-2020-x","article-title":"Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis","volume":"185","author":"Sugahara","year":"2009","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.jhepr.2026.101765_bib51","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00066-014-0604-6","article-title":"Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"190","author":"Lee","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.jhepr.2026.101765_bib52","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1159\/000517440","article-title":"Controlling major portal vein invasion progression during lenvatinib treatment by carbon-ion radiotherapy in patients with advanced hepatocellular carcinoma","volume":"14","author":"Yoshida","year":"2021","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.jhepr.2026.101765_bib53","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41416-020-0942-3","article-title":"Radiation-induced bystander and abscopal effects: important lessons from preclinical models","volume":"123","author":"Daguenet","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.101765_bib54","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhepr.2026.101765_bib55","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101765_bib56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101765_bib57","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101765_bib58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.101765_bib59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101765_bib60","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1038\/s41467-023-43462-1","article-title":"Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101765_bib61","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101765_bib62","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2026.101765_bib63","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor A","volume":"24","author":"Perez-Gutierrez","year":"2023","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:48:47Z","timestamp":1779414527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2589555926000364"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101765","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101765","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101765"}}